Why Gilead Sciences Stock Lagged Behind Other Biotechs in April

Why Gilead Sciences Stock Lagged Behind Other Biotechs in April


The iShares Nasdaq Biotechnology Index Gilead's stock has so far failed to take part in the broader biotech rally this year due to a continually worsening outlook for its hepatitis C franchise. In the first quarter of this year, for example, the company missed consensus estimates on revenue by $126 million because of its plummeting hepatitis C product sales both domestically and abroad.



from Biotech News